MedTrace Logo

A Study of the Safety of Rabeprazole Administered to Adults With Gastroesophageal Reflux Disease (GERD)

NCT00216489 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 191

Last updated 2010-04-26

No results posted yet for this study

Summary

The purpose of the study is to confirm the safety and effectiveness of rabeprazole in the treatment of patients with erosive or ulcerative gastroesophageal reflux disease (GERD) in routine primary health care.

Conditions

  • Gastroesophageal Reflux
  • Heartburn

Interventions

DRUG

rabeprazole sodium

Sponsors & Collaborators

  • Janssen Cilag Pharmaceutica S.A.C.I., Greece

    lead INDUSTRY

Principal Investigators

  • Janssen-Cilag Pharmaceutica S.A.C.I. Clinical Trial · Janssen-Cilag Pharmaceutica S.A.C.I.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-03-31
Completion
2005-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00216489 on ClinicalTrials.gov